SCHEMBL22609299

SCHEMBL22609299

CCOC(=O)C(=[N+]=[N-])C(=O)Cc1ccc(Br)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.46
KMT2A Q03164 4/20 0.46
MAPK1 P28482 2/20 0.46
S1PR4 O95977 1/20 0.46
LMNA P02545 1/20 0.46
MAPT P10636 1/20 0.46
S1PR1 P21453 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
CYP1A2 P05177 1/20 0.40
CYP2C9 P11712 1/20 0.40
MME P08473 1/20 0.39
ACE P12821 1/20 0.39
EGFR P00533 1/20 0.38
ERBB2 P04626 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
HTT P42858 1/20 0.38
KDM4E B2RXH2 1/20 0.38
GLA P06280 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
POLB P06746 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22684781 0.88 MEN1 (0.44) MEN1KMT2ALMNAMAPTCYP1A2
SCHEMBL21176846 0.86 KMT2A (0.46) MEN1KMT2ALMNAMAPTNPSR1
SCHEMBL28366287 0.85 CES2 (0.47) MEN1KMT2AMAPK1MAPTSMN1; SMN2
SCHEMBL603711 0.84 HTT (0.45) MEN1KMT2ALMNAEGFRSMN1; SMN2
SCHEMBL7636374 0.83 KMT2A (0.54) MEN1KMT2AMAPK1S1PR4LMNA
SCHEMBL10140684 0.80 KMT2A (0.41) MEN1KMT2AEGFRERBB2SMN1; SMN2
SCHEMBL22230717 0.79 MAPT (0.48) MEN1KMT2AMAPK1S1PR4LMNA
SCHEMBL22230720 0.75 MAPT (0.43) MEN1KMT2AMAPK1S1PR4LMNA
SCHEMBL15964601 0.75 KMT2A (0.49) MEN1KMT2AMAPK1S1PR4LMNA
Dimethylamine SCHEMBL8690366 0.74 KMT2A (0.46) MEN1KMT2AMAPK1S1PR4LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210171503-A1 GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF ORFAN BIOTECH SL (ES) 2021-06-10 US disclosed
EP-3731840-A1 GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF Orfan Biotech Inc. (US) 2020-11-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210171503-A1 GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF PNPO, XDH, GLS MEN1 3943/4885KMT2A 3407/4885MAPK1 826/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.